Tribendimidine in the treatment of liver fluke infection in China
| ISRCTN | ISRCTN80829842 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN80829842 |
| Protocol serial number | N/A |
| Sponsor | Medical Research Council (UK) |
| Funders | Department For International Development [DFID] (UK), Medical Research Council (MRC) (UK), Wellcome Trust (UK) ref: G1100699 |
- Submission date
- 07/03/2012
- Registration date
- 20/03/2012
- Last edited
- 27/08/2013
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Clonorchiasis, a disease caused by the oriental liver fluke Clonorchis sinensis, is of considerable public health importance. The disease is constantly present in the Peoples Republic of China, Taiwan, Vietnam, and the Republic of Korea, where an estimated 601 million people are at risk and more than 35 million people are infected. There is currently no vaccine available for prevention of clonorchiasis and chemotherapy is the main treatment. However, chemotherapy of clonorchiasis relies on a single drug called praziquantel. Efforts are underway to administer praziquantel more widely, in preventive chemotherapy campaigns. There is some concern that this strategy might result in the development and spread of drug-resistant parasites. There is a need for discovery and development of new drugs. The aim of this study is to assess how well oral tribendimidine works in patients infected with C. sinensis.
Who can participate?
75 individuals with a parasitological-confirmed infection with C. sinensis
What does the study involve?
Patients will be randomly allocated to one of three groups:
- single oral dose of 400 mg tribendimidine
- oral doses of 400 mg tribendimidine daily for 3 days
- praziquantel (25 mg/kg 3 times a day) for 2 consecutive days
What are the possible benefits and risks of participating?
The two drugs which are compared are well known, widely used and have little adverse events. All children enrolled in the study will benefit from a treatment against liver fluke infection and soil transmitted helminths. All diagnosed parasitic infections will be treated according to national guidelines.
Where is the study run from?
Guangdong province, China.
When is study starting and how long is it expected to run for?
The study will last for 5-6 weeks and will take place in March/April 2012.
Who is funding the study?
The study will be funded by DFID/Wellcome Trust/MRC.
Who is the main contact?
Professor Jennifer Keiser
Contact information
Scientific
Socinstr. 57
Basel
4051
Switzerland
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized exploratory open-label phase II trial with three treatment arms |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Tribendimidine in the treatment of Clonorchis sinensis infection in the Peoples Republic of China |
| Study objectives | Tribendimidine achieves a higher efficacy than praziquantel in the treatment of Clonorchis infections Follow up to http://www.controlled-trials.com/ISRCTN23425032 |
| Ethics approval(s) | Ethikkomission Beider, Basel, 09 February 2012 ref: 375/11 |
| Health condition(s) or problem(s) studied | Liver fluke infections (Clonorchis sinesis) |
| Intervention | Group 1: single oral dose of 400 mg tribendimidine Group 2: oral doses of 400 mg tribendimidine daily for 3 days Group 3: praziquantel (25 mg/kg 3 times a day) for 2 consecutive days Follow up is 21 days after treatment. Praziquantel brand names are Biltricide® and Cesol®. |
| Intervention type | Drug |
| Phase | Phase II |
| Drug / device / biological / vaccine name(s) | Praziquantel, tribendimidine |
| Primary outcome measure(s) |
Cure rates and egg reduction rates three weeks after treatment: |
| Key secondary outcome measure(s) |
Adverse events due to specific treatment: |
| Completion date | 10/05/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 75 |
| Key inclusion criteria | 1. Patients (adults aged ≥18 years) infected with C. sinensis, as assessed by the presence of eggs in the stool 2. Signed written informed consent 3. Able and willing to be examined by a study physician at the beginning of the study and at the end-of study follow-up survey (3 - 4 weeks post-treatment) 4. Able and willing to provide multiple stool samples at the beginning and end of study 5. Absence of major systemic illnesses, psychiatric and neurological disorders as assessed by the medical doctor, upon initial clinical assessment 6. No known or reported hypersensitivity to tribendimidine or praziquantel 7. No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease 8. For females, not pregnant in the first trimester, as assessed by a female nurse (interview and pregnancy test if need be), upon initial clinical assessment |
| Key exclusion criteria | 1. For females, pregnancy in first trimester 2. Presence of any abnormal medical condition, judged by the study physician 3. History of acute or severe chronic disease 4. Known or reported hypersensitivity to tribendimidine or praziquantel 5. Known or reported psychiatric or neurological disorders 6. Use of any anthelmintic within the past month 7. Attending other clinical trials during the study 8. Absence of signed written informed consent sheet |
| Date of first enrolment | 10/03/2012 |
| Date of final enrolment | 10/05/2012 |
Locations
Countries of recruitment
- China
- Switzerland
Study participating centre
4051
Switzerland
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/04/2013 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
